Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

Overview of attention for article published in Blood, August 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

policy: 1 policy source
twitter: 38 X users
patent: 2 patents

facebook: 1 Facebook page
googleplus: 1 Google+ user

Readers on

mendeley: 150 Mendeley

So far, Altmetric has seen 1 policy document that references this research output.

Decitabine-Cedazuridine (Inqovi) for MDS - Details - Decitabine-Cedazuridine (Inqovi) for MDS - Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 07 Jul 2020

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.